Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hyperimmune Plasma for Critical Patients With COVID-19 (COV19-PLASMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04321421
Recruitment Status : Completed
First Posted : March 25, 2020
Last Update Posted : May 28, 2020
Sponsor:
Collaborator:
OSPEDALE CARLO POMA ASST MANTOVA
Information provided by (Responsible Party):
Cesare Perotti, Foundation IRCCS San Matteo Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : April 28, 2020
Actual Study Completion Date : May 7, 2020
Publications:
WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. 2020. https://www.who. int/docs/default-source/coronaviruse/clinical-management-of-novel-cov. pdf (accessed Feb 20, 2020).
WHO. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks. 2014. http://apps.who.int/iris/rest/ bitstreams/604045/retrieve (accessed Feb 20, 2020).

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):